Emerging Applications of "Omics" in Personalized Medicine and Drug Discovery

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (31 March 2020) | Viewed by 8918

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA
Interests: untargeted and targeted metabolomics; inborn errors of metabolism; assays development
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent remarkable advances in “omics” technologies and network analysis platforms have opened new opportunities in preclinical and clinical investigations. Specifically, various "omics" technologies have substantially contributed to our understanding of complex phenotypes, genotypes, and disease pathophysiologies. In the drug development field, "omics" provide valuable tools in the identification of new therapeutic targets and a new paradigm in safety and efficacy studies.  Although many challenges still have to be addressed for the bench to bedside translation , "omics" platforms have the potential to transform medicine from traditional to more personalized approach while advancing prognostic, diagnostic and therapeutic outcomes markers. Consequently, the more personalized approach will lay the foundation to more effective medical interventions for the benefit of patients and healthcare providers.

We are inviting the submission of original and review articles to a Special Issue of the Journal of Personalized Medicine to cover the expanding field of "omics" integration in personalized medicine and drug discovery. The manuscript can cover case reports, translational, preclinical and clinical studies or innovative technologies and network analysis developments that challenge and advance the field.

Dr. Yana Sandlers
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Metabolomics
  • proteomics
  • genomics
  • transcriptomics
  • NMR
  • mass spectrometry
  • pathway computational modeling
  • prognostic/diagnostic and therapeutic outcomes markers
  • personalized medicine
  • pharmacogenomics
  • drug development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2478 KiB  
Article
A Web-Based Pharmacogenomics Search Tool for Precision Medicine in Perioperative Care
by Sara Zarei, Yensea Costas, Gloria Orozco, Michelle Zaydlin, Ali Mirtar, Mohammad Abouali, Cristina Diaz-Marty, Golnoush Akhlaghipour, Pablo Fernandez Altamirano, Anel R. Gonzalez Cardona, Luz E. Reiley and Hooman Mirzakhani
J. Pers. Med. 2020, 10(3), 65; https://doi.org/10.3390/jpm10030065 - 21 Jul 2020
Cited by 6 | Viewed by 4133
Abstract
Background: Precision medicine represents an evolving approach to improve treatment efficacy by modifying it to individual patient’s gene variation. Pharmacogenetics, an applicable branch of precision medicine, identifies patient’s predisposing genotypes that alter the clinical outcome of the drug, hence preventing serious adverse drug [...] Read more.
Background: Precision medicine represents an evolving approach to improve treatment efficacy by modifying it to individual patient’s gene variation. Pharmacogenetics, an applicable branch of precision medicine, identifies patient’s predisposing genotypes that alter the clinical outcome of the drug, hence preventing serious adverse drug reactions. Pharmacogenetics has been extensively applied to various fields of medicine, but in the field of anesthesiology and preoperative medicine, it has been unexploited. Although the US Food and Drug Administration (FDA) has a table of pharmacogenomics biomarkers and pharmacogenetics, this table only includes general side effects of the included drugs. Thus, the existing FDA table offers limited information on genetic variations that may increase drug side effects. Aims: The purpose of this paper is to provide a web-based pharmacogenomics search tool composed of a comprehensive list of medications that have pharmacogenetic relevance to perioperative medicine that might also have application in other fields of medicine. Method: For this investigation, the FDA table of pharmacogenomics biomarkers in drug labeling was utilized as an in-depth of drugs to construct our pharmacogenetics drug table. We performed a literature search for drug–gene interactions using the unique list of drugs in the FDA table. Publications containing the drug–gene interactions were identified and reviewed. Additional drugs and extracted gene-interactions in the identified publications were added to the constructed drug table. Result: Our tool provides a comprehensive pharmacogenetic drug table including 258 drugs with a total of 461 drug–gene interactions and their corresponding gene variations that might cause modifications in drug efficacy, pharmacokinetics, pharmacodynamics and adverse reactions. This tool is freely accessible online and can be applied as a web-based search instrument for drug–gene interactions in different fields of medicine, including perioperative medicine. Conclusion: In this research, we collected drug–gene interactions in a web-based searchable tool that could be used by physicians to expand their field knowledge in pharmacogenetics and facilitate their clinical decision making. This precision medicine tool could further serve in establishing a comprehensive perioperative pharmacogenomics database that also includes different fields of medicine that could influence the outcome of perioperative medicine. Full article
Show Figures

Figure 1

19 pages, 270 KiB  
Article
Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan
by Laith N. AL-Eitan, Doaa M. Rababa’h, Nancy M. Hakooz, Mansour A. Alghamdi and Rana B. Dajani
J. Pers. Med. 2020, 10(1), 2; https://doi.org/10.3390/jpm10010002 - 6 Jan 2020
Cited by 7 | Viewed by 4330
Abstract
Several genetic variants have been identified that cause variation among different populations and even within individuals of a similar descent. This leads to interindividual variations in the optimal dose of the drug that is required to sustain the treatment efficiency. In this study, [...] Read more.
Several genetic variants have been identified that cause variation among different populations and even within individuals of a similar descent. This leads to interindividual variations in the optimal dose of the drug that is required to sustain the treatment efficiency. In this study, 56 single nucleotide polymorphisms (SNPs) within several pharmacogenes were analyzed in 128 unrelated subjects from a genetically isolated group of Circassian people living in Jordan. We also compared these variant distributions to other ethnic groups that are available at two databases (Genome 1000 and eXAC). Our results revealed that the distribution of allele frequencies within genes among Circassians in Jordan showed similarities and disparities when compared to other populations. This study provides a powerful base for clinically relevant SNPs to enhance medical research and future pharmacogenomic studies. Rare variants detected in isolated populations can significantly guide to novel loci involved in the development of clinically relevant traits. Full article
Back to TopTop